Grant: Collaborative Research and Development Grants
École Polytechnique de Montréal
$92,504.00
Decoration and Dimerization of Chimeric Proteins Mediated by Coiled-Coil Interactions
EF 2019-20
Résumé
The pharmaceutical industry is one of the most profitable Canadian manufacturing sector and its strength relies on continuous innovation, with formulation at the core of its strategic development. While nano-medicine (e.g. drug-antibody conjugates and intricate assemblies of proteins) are the latest and most-promising generation of therapeutics, the industry still struggles to design and produce them efficiently.Forbius, a Canadian company focusing on the development of novel biotherapeutics to treat rare diseases, is the industrial partner of this Collaborative Research and Development Grant application. Through this project, a collaboration between researchers at Polytechnique Montréal, Université de Montréal and the R&D team at Forbius is proposed in order to design Forbius' next-generation therapeutics. At the heart of the proposed research is a versatile peptide-based conjugation platform intensively exploited by the team at Polytechnique Montreal, that will be applied to engineer 1) novel approaches for the conjugation of drugs to antibodies, 2) unnatural dimers of proteins to be tested as potential inhibitors, and 3) a portfolio of enabling technologies to favor the production and the purification of the peptides and proteins being produced in the context of the project.The project will involve 3 HQPs - two post-doctoral fellows and one PhD student - that will be trained in a multidisciplinary environment and exposed to the industrial challenges faced by small Canadian pharmaceutical companies. With 2 drugs in clinical trials phase, Forbius is now rapidly expanding its R&D activities and actively recruiting. Furthermore, within Canada only, more than twenty local small biotech companies are currently designing similar products. They all are, in addition to the Canadian branches of the multinational pharmaceutical companies, potential employers of the HQP trained during this project. Indeed, HQPs are currently in high demand in the biomanufacturing sector; this represents a significant outcome of the project to sustain the growth of these companies in Canada.
Programme
Collaborative Research and Development Grants
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
537306-2018
Name nom
DeCrescenzo, Gregory
Department département
Génie chimique
Organization id
64
Institution établissement
École Polytechnique de Montréal
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2019
Competition year année de concours
2018
Award amount
92504
Program id
CRDPJ
Program name en
Collaborative Research and Development Grants
Program name fr
Subventions de recherche et développement coopérative
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
5403
Research subject group en
Biochemistry
Research subject group fr
Biochimie
Research subject en
Proteins and peptides, amino acids
Research subject fr
Protéines et peptides, acides aminés
Installment
inst:1 - 1
Partie
1
Nb partie
1
Application title
Decoration and Dimerization of Chimeric Proteins Mediated by Coiled-Coil Interactions
Keyword
NSERC
Application summary
The pharmaceutical industry is one of the most profitable Canadian manufacturing sector and its strength relies on continuous innovation, with formulation at the core of its strategic development. While nano-medicine (e.g. drug-antibody conjugates and intricate assemblies of proteins) are the latest and most-promising generation of therapeutics, the industry still struggles to design and produce them efficiently.Forbius, a Canadian company focusing on the development of novel biotherapeutics to treat rare diseases, is the industrial partner of this Collaborative Research and Development Grant application. Through this project, a collaboration between researchers at Polytechnique Montréal, Université de Montréal and the R&D team at Forbius is proposed in order to design Forbius' next-generation therapeutics. At the heart of the proposed research is a versatile peptide-based conjugation platform intensively exploited by the team at Polytechnique Montreal, that will be applied to engineer 1) novel approaches for the conjugation of drugs to antibodies, 2) unnatural dimers of proteins to be tested as potential inhibitors, and 3) a portfolio of enabling technologies to favor the production and the purification of the peptides and proteins being produced in the context of the project.The project will involve 3 HQPs - two post-doctoral fellows and one PhD student - that will be trained in a multidisciplinary environment and exposed to the industrial challenges faced by small Canadian pharmaceutical companies. With 2 drugs in clinical trials phase, Forbius is now rapidly expanding its R&D activities and actively recruiting. Furthermore, within Canada only, more than twenty local small biotech companies are currently designing similar products. They all are, in addition to the Canadian branches of the multinational pharmaceutical companies, potential employers of the HQP trained during this project. Indeed, HQPs are currently in high demand in the biomanufacturing sector; this represents a significant outcome of the project to sustain the growth of these companies in Canada.